About us

Improved treatments through novel drug delivery technology

About us

Synartro AB

Synartro is a Swedish life science company developing local injection treatments to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our novel delivery technology with existing proven drugs.

Our lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). This disease leaves up to 50% of patients without adequate pain relief.


Bengt Lindqvist, part of the team behind the hyaluronic acid substance Healon from Pharmacia, is the inventor of our patented hyaluronan-based drug delivery platform. After the initial discovery, he teamed up with other skilled chemists to commence development of the compound SYN321, where diclofenac is linked to the drug delivery platform. In 2013, an animal study showed that SYN321 provided a sustained release of diclofenac in knee joints of horses, without observed side effects.

In 2020, a US patent was granted for the drug delivery platform. Since then, development activities have intensified.